Amgen Says 2007 Profits Will Top October Projections
This article was originally published in The Pink Sheet Daily
Executive Summary
California biotech cites cost-cutting measures as reason for upgraded earnings per share guidance of $4.30.
You may also be interested in...
Amgen PREPAREs Aranesp For Yet Another Hit
Phase III interim results evaluating the anemia drug in cancer setting show more deaths, higher rate of tumor progression.
Amgen, J&J Revise Labels For Aranesp, Epogen, Procrit
Amgen says it will present new data to CMS in effort to persuade agency to modify its National Coverage Decision on ESAs.
Amgen EPO Patent Win Over Roche Could Derail Mircera Launch
Boston jury finds Roche’s Mircera infringes Amgen’s erythropoietin patents and that all five Amgen patents are valid.